Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ciclesonide
Drug ID BADD_D00460
Description Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
Indications and Usage For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
Marketing Status approved; investigational
ATC Code R01AD13; R03BA08
DrugBank ID DB01410
KEGG ID D01703
MeSH ID C120481
PubChem ID 6918155
TTD Drug ID D0K7HU
NDC Product Code 70515-711; 53104-7633; 70515-712; 70515-701; 64918-1900; 24002-0016; 64918-1112; 70515-737
UNII S59502J185
Synonyms ciclesonide | (R)-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate | Alvesco | Omnaris
Chemical Information
Molecular Formula C32H44O7
CAS Registry Number 126544-47-6
SMILES CC(C)C(=O)OCC(=O)C12C(CC3C1(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)OC(O2)C6CCCCC6
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nausea07.01.07.0010.000947%
Night sweats23.02.03.006; 08.01.03.031--Not Available
Oedema peripheral08.01.07.007; 02.05.04.007; 14.05.06.0110.000379%
Oral candidiasis11.03.03.004; 07.05.07.001--Not Available
Osteoporosis15.02.03.002; 14.04.04.002--
Pain in extremity15.03.04.010--
Palpitations02.11.04.012--
Paraesthesia17.02.06.005; 23.03.03.094--
Personality change19.05.01.006; 17.02.05.019--
Pharyngeal oedema23.04.01.016; 22.04.05.003; 10.01.05.016--Not Available
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Pharyngitis streptococcal22.07.04.001; 11.02.06.002--Not Available
Pleural effusion22.05.02.0020.000379%
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Presyncope02.11.04.013; 24.06.02.010; 17.02.05.009--
Productive cough22.02.03.005--
Pruritus23.03.12.0010.001137%
Pulmonary congestion24.03.08.001; 22.01.03.002; 02.05.02.002--Not Available
Pulmonary embolism22.06.02.001; 24.01.06.0010.000379%Not Available
Pulmonary fibrosis22.01.02.0060.000379%
Pyrexia08.05.02.0030.000568%
Rales22.12.01.011--Not Available
Rash23.03.13.0010.000568%Not Available
Rash papular23.03.13.017--Not Available
Respiratory disorder22.02.07.0020.000568%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000379%
Rhinitis11.01.13.004; 22.07.03.006--
Rhinitis allergic22.04.04.003; 10.01.04.003--
Rhinorrhoea22.12.03.021--
Secondary adrenocortical insufficiency05.03.04.012; 14.11.01.014--Not Available
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages